Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing

3rd April 2018 Uncategorised 0

Sanofi’s new atopic dermatitis launch Dupixent hit a roadblock with the influential cost-effectiveness gatekeepers in England. NICE figures the drug works—and offers an option for patients who really need one—but isn’t sure it’s worth the price.

More: Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing
Source: fierce